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Aims To determine the prognostic value of multilevel assessment of fibrosis in dilated cardiomyopathy (DCM) patients.
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Methods
and results
We quantified fibrosis in 209 DCM patients at three levels: (i) non-invasive late gadolinium enhancement (LGE) at
cardiac magnetic resonance (CMR); (ii) blood biomarkers [amino-terminal propeptide of procollagen type III (PIIINP)
and carboxy-terminal propeptide of procollagen type I (PICP)], (iii) invasive endomyocardial biopsy (EMB) (collagen
volume fraction, CVF). Both LGE and elevated blood PICP levels, but neither PIIINP nor CVF predicted a worse
outcome defined as death, heart transplantation, heart failure hospitalization, or life-threatening arrhythmias, after
adjusting for known clinical predictors [adjusted hazard ratios: LGE 3.54, 95% confidence interval (CI) 1.90–6.60;
P< 0.001 and PICP 1.02, 95% CI 1.01–1.03; P = 0.001]. The combination of LGE and PICP provided the highest
prognostic benefit in prediction (likelihood ratio test P = 0.007) and reclassification (net reclassification index: 0.28,
P = 0.02; and integrated discrimination improvement index: 0.139, P = 0.01) when added to the clinical prediction
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model. Moreover, patients with a combination of LGE and elevated PICP (LGE+/PICP+) had the worst prognosis
(log-rank P< 0.001). RNA-sequencing and gene enrichment analysis of EMB showed an increased expression of
pro-fibrotic and pro-inflammatory pathways in patients with high levels of fibrosis (LGE+/PICP+) compared to
patients with low levels of fibrosis (LGE-/PICP-). This would suggest the validity of myocardial fibrosis detection by
LGE and PICP, as the subsequent generated fibrotic risk profiles are associated with distinct cardiac transcriptomic
profiles.
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Conclusion The combination of myocardial fibrosis at CMR and circulating PICP levels provides additive prognostic value
accompanied by a pro-fibrotic and pro-inflammatory transcriptomic profile in DCM patients with LGE and elevated
PICP.
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Graphical Abstract
Multilevel assessment of myocardial fibrosis demonstrates significant correlations between histology, non-invasive imaging, and blood markers.
A combined multi-parametric approach with carboxy-terminal propeptide of procollagen type I (PICP) and late gadolinium enhancement (LGE)
allows the best risk stratification of idiopathic dilated cardiomyopathy (DCM) patients, accompanied with a profile of high expression of combined
pro-inflammatory and pro-fibrotic genes, indicating a potential marker for disease activity.
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Keywords Idiopathic dilated cardiomyopathy • Fibrosis • Late gadolinium enhancement • Endomyocardial
biopsy • PICP • PIIINP
Introduction
Despite advances in therapy, idiopathic dilated cardiomyopa-





. transplantation and has a mortality rate of approximately 20% at
5 years.1 Idiopathic DCM is a multifactorial disease with varying
presentation and evolution.2 Accurate phenotyping, enabling a
more personalized approach to improve outcomes, remains a
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therapeutic goal.3 Myocardial fibrosis is a fundamental process in
cardiac remodelling and a key player in idiopathic DCM and its
progression.3,4
Non-invasive imaging, blood analysis and endomyocardial biopsy
(EMB) are used to detect fibrosis. Current risk stratification only
considers these different levels of fibrosis separately. Late gadolin-
ium enhancement (LGE) cardiac magnetic resonance (CMR) imag-
ing detects focal fibrosis in approximately 30% of patients.1,5 The
presence of LGE provides incremental prognostic value in idio-
pathic DCM patients beyond well-known clinical predictors.1,5,6
However, the method detects focal replacement fibrosis and there-
fore underestimates overall interstitial fibrosis.4 Therefore, the
presence and amount of LGE-CMR remains incomplete in evalu-
ating the total burden of myocardial fibrosis and its potential to
predict outcome.
Circulating fibrosis markers could provide additional information
on a pro-fibrotic state, as they reflect collagen turnover not only
in the heart, but also in the vessels, liver and bone among other
organs.7 Carboxy-terminal propeptide of procollagen type I (PICP)
and the amino-terminal propeptide of procollagen type III (PIIINP)
are the only two collagen-derived serum peptides associated with
cardiac fibrosis as seen on histology.7 Increased levels of the peptide
predict adverse outcome in patients with ischaemic heart failure
(HF) and HF with preserved ejection fraction.8–10 Whether PICP
or PIIINP have prognostic value beyond LGE has never been
studied and their prognostic role in idiopathic DCM is unknown.
EMB may help to detect fibrosis on a tissue level but is limited
by small tissue samples and sampling error.11 Studies evaluating
EMB-derived fibrosis and prognosis in DCM patients are therefore
scarce, with conflicting results.12,13
The aim of this study is to evaluate the prognostic value of mul-
tilevel fibrosis assessment in idiopathic DCM patients integrating
(i) non-invasive imaging (LGE-CMR), (ii) circulating collagen
turnover markers (PICP, PIIINP), and (iii) invasive cardiac biopsies.
Methods
A more detailed description of the methods is in the online supple-
mentary material.
Study population
Consecutive idiopathic DCM patients undergoing CMR, blood
sampling and EMB were prospectively enrolled in the Maastricht
Cardiomyopathy Registry between 2004 and 2017 (n= 928, online sup-
plementary Figure S1), as described previously.2 The diagnosis of DCM
was confirmed using the World Health Organization/International
Society and Federation of Cardiology definition, based on reduced
left ventricular ejection fraction (LVEF) and increased left ventricular
end-diastolic volume (LVEDVi) indexed to body surface area (BSA),
compared to published age- and sex-specific reference values.14,15 In
keeping with guidelines,15–17 exclusion criteria included: (i) myocardial
infarction and/or significant coronary artery disease (stenosis >50%,
ruled out by coronary artery angiography or computed tomography)
and/or presence of infarct patterns of LGE on CMR; (ii) primary
valvular disease; (iii) hypertensive or congenital heart disease; (iv)



















































































.. (vi) hypertrophic, restrictive, or peripartum cardiomyopathy. Patients
included in this registry between 2004 and 2016 were selected for
this study based on the following inclusion criteria: (i) time between
CMR and biopsy <3 months; and (ii) availability of spare serum to
determine fibrosis markers. Patients with renal dysfunction [estimated
glomerular filtration rate (GFR) <30 mL/min], known active neoplasia,
active hepatitis or liver cirrhosis, and overt inflammatory, metabolic,
or bone disease (n = 27, 11%), were excluded (online supplementary
Figure S1).18
Patients that fulfil the diagnostic criteria of DCM are referred to
our specialized outpatient clinic. The patients’ first visit at the DCM
outpatient clinic is defined as baseline moment. At baseline, a standard
care protocol is used for the clinical diagnostic work-up of DCM
patients including medical history taking, physical examination, blood
sampling, 12-lead electrocardiogram, and CMR. EMB is performed if
a patient shows persistent cardiac dysfunction under stable optimal
medical therapy. Storage of blood samples takes place at the same time
as the EMB is performed.
All patients underwent a physical examination, blood sampling,
12-lead electrocardiogram, 24 h Holter monitoring, CMR, and EMB
at baseline. The study was performed according to the Declaration
of Helsinki and was approved by the institutional Medical Ethics
Committee. All patients gave written informed consent.
Follow-up
Information about the occurrence of adverse events at follow-up
was retrieved from the medical records, municipal population register
and/or telephone contact with general practitioners. Follow-up data
on all-cause mortality, heart transplantation, life-threatening ventricu-
lar arrhythmias, and HF hospitalization were collected using medical
records. End of follow-up was defined as September 2019, resulting in
at least 2 years [median 75 (54–95) months] of follow-up in all patients.
No patient was lost to follow-up. Primary endpoint was event-free sur-
vival, including all aforementioned events. Life-threatening ventricular
arrhythmias were defined as ventricular fibrillation [with or without
implantable cardioverter-defibrillator (ICD) shock], haemodynamic
unstable ventricular tachycardia, or sustained ventricular tachycardia
with ICD shock.
Magnetic resonance imaging
Cardiac magnetic resonance was performed on a 1.5 T magnetic
resonance imaging system (Intera, Philips Medical Systems, Best,
The Netherlands) using a standardized protocol, that included cine
and LGE imaging in the long and short axis of the left ventricle.
LGE imaging was performed 10–15 min after an intravenous bolus
of 0.2 mmol/kg body weight gadolinium-diethylenetriaminepentaacetic
acid (Gadobutrol, Bayer, Berlin, Germany). Two observers, blinded to
clinical data, analysed the cine and LGE images using commercially avail-
able software (CAAS MRV3.0, Pie Medical Imaging, Maastricht, The
Netherlands). LGE (focal fibrosis) was considered present or absent
if reproducibly observed in multiple views (i.e. long- and short-axis
planes) and extending beyond the localized ventricular insertion areas.
Typical right ventricular insertion areas of fibrosis were excluded.
LGE quantification was performed using the full width at half maxi-
mum method.19 Every patient underwent CMR during the diagnostic
work-up. No patient had prior implantation of an electronic device [i.e.
pacemaker, ICD, or cardiac resynchronization therapy (CRT)] at time
of CMR.
© 2021 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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Figure 1 Example of a patient with late gadolinium enhancement on cardiac magnetic resonance and corresponding histology. (A) Cardiac
magnetic resonance image in short-axis view with visible inferoseptal late gadolinium enhancement. (B) Sirius red staining corresponding to
17% of total endomyocardial biopsy.
Biochemical studies
Blood sampling was performed at the time of the EMB proce-
dure. Plasma amino-terminal propeptide of brain natriuretic peptide
(NT-proBNP) was measured using an electrochemiluminescence
immunoassay (Roche Diagnostics, Mannheim, Germany) in all
patients. In addition, serum PICP was measured by an enzyme-linked
immunosorbent assay method (Quidel Corporation, San Diego, CA,
USA) and PIIINP by a radioimmunoassay (Orion Diagnostica, Espoo,
Finland).
Endomyocardial biopsy
At least six EMB samples were taken from the right ventricular
septum via the internal jugular vein using a transcatheter bioptome
(Cordis, Miami, FL, USA). In all patients, three specimens were used
for immunohistological analysis and three for the detection of viral
genomes.2 Histopathological tests were done on 4 μm-thick tissue
sections from formalin-fixed, paraffin-embedded EMBs, and stained
with haematoxylin and eosin, Sirius red, CD3+, CD45+ and CD68+.
Since the initiation of the Maastricht CMP registry, in all included
patients, cell counts were noted as cells/mm2. Increased cardiac inflam-
mation was defined as ≥14 CD45, including up to 4 CD68-infiltrating
cells/mm2 according to the current European Society of Cardiology
position statement.20 To evaluate histological collagen volume fraction
(CVF), five to seven high-power (200×) magnification digital images,
covering the total biopsy, and one to two 40× magnification images
were acquired per patient for semiautomated analysis (ImageJ ver-
sion 1.50b, National Institutes of Health, Bethesda, MD, USA).21,22
CVF was quantified as percentage tissue positive for Sirius red of the
total myocardial area, excluding subendocardial and perivascular areas
(Figure 1). The average of the quantification of the different images was
considered as the final value of fibrosis for the patient.
RNA-sequencing and bioinformatic
analysis
RNA was isolated from EMBs in a representative group of patients with





















































. mRNA-sequencing library was generated using TruSeq mRNA sample
preparation kit (Illumina) and sequenced on the NextSeq 500 (Illu-
mina). Molecular pathway analysis was performed using the bioinfor-
matics tool Ingenuity® pathway analysis (IPA®) and gene enrichment
analysis using predefined Kyoto Encyclopedia of Genes and Genomes
(KEGG) pathways and Gene Ontology (GO) biological processes.
Statistical analysis
Variables are displayed as numbers (percentage), mean± standard devi-
ation, or median [interquartile range] as appropriate. Normality was
demonstrated by the Shapiro–Wilk test. Non-parametric distributed
variables were examined after logarithmic transformation. Compar-
isons between groups were performed using X2 tests (or Fisher exact
test where necessary) for categorical data and one-way ANOVA or
Kruskal–Wallis H test for continuous data, as appropriate. Pearson
correlation coefficient was used to examine the relationship between
variables.
Kaplan–Meier survival curves were estimated and differences
between groups were assessed by the log-rank test. Unadjusted and
adjusted Cox proportional hazards regression analysis was performed
to determine the hazard ratio (HR) and subsequent 95% confidence
interval (CI). Cubic spline regression models were used to test
whether the adjusted associations between continuous fibrosis mark-
ers and outcome deviate from a linear trend. The spline analysis was
knotted at 25th, 50th, and 75th percentiles. Covariates known to
be predictive of outcome in DCM were used for adjustment: LVEF,
estimated GFR, body mass index (BMI), NT-proBNP, mineralocor-
ticoid receptor antagonist (MRA) use, diabetes, sex and age.6,23 To
test whether fibrosis markers improved risk prediction of the clinical
parameters, we used Harrel’s C-index, a likelihood ratio (LHR) test,
as well as the continuous net reclassification index (NRI) and the
integrated discrimination improvement (IDI).
For the additional transcriptomic analysis, the study population was
simplified and categorized into presence (LGE+) or absence (LGE-) of
LGE with subgroups of above (PICP+) and below (PICP-) median PICP
levels resulting in four groups, in order to analyse the RNA-sequencing
data and evaluate the sub-groups’ associations with outcome. Statistical
analysis was performed using SPSS 25.0 software (IBM Corp., Armonk,
© 2021 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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A total of 209 patients were included. Baseline characteristics are
summarized in Table 1. Male sex predominated (65%), and the age
at diagnosis was 54±13 years. Approximately one-third presented
with New York Heart Association (NYHA) class ≥III, and one-third
with LVEF <35%. In the majority of patients (79%), EMB was
performed in an outpatient clinical setting. The median duration
between diagnostic CMR and EMB was 30 [6–50] days.
Correlation of PICP and PIIINP levels
to cardiac late gadolinium enhancement,
histological collagen volume fraction
and cardiac function
Both PICP and PIIINP levels were significantly higher in
LGE-positive as compared to LGE-negative patients (91 [67–112]
ng/mL vs. 77 [62–97] ng/mL, P = 0.02 and 5.5 [3.5–7.5] ng/mL
vs. 4.1 [3.0–5.6] ng/mL, P< 0.01, respectively). Circulating PICP
correlated moderately (R2 = 0.39, P< 0.001), whereas PIIINP
correlated weakly with LGE extent (R2 = 0.14, P = 0.01; online
supplementary Figure S2A and S2B). Histological CVF correlated
moderately with LGE extent (R2 = 0.37, P< 0.0001, online
supplementary Figure S2C).
PICP levels and histological CVF correlated in the total cohort
(R2 = 0.17, P = 0.001, Figure 2A), even more so in patients
with severe HF in terms of LVEF <35% (R2 = 0.43, P< 0.001),
NYHA class ≥III (R2 = 0.53, P< 0.001), or both (R2 = 0.68,
P< 0.001, Figure 2B–D). Serum PIIINP had only weak correlations
with histological CVF in all aforementioned subgroups of HF
severity (online supplementary Figure S3). Additionally, no clinically
relevant correlations were found between PICP or PIIINP and
other clinical parameters, namely NT-proBNP, GFR, age and BSA
(PICP: NT-proBNP R2 = 0.03, P = 0.008; GFR R2 = 0.0003,
P = 0.81; age R2 = 0.001, P = 0.60; BSA R2 = 0.00004, P = 0.93;
PIIINP: NT-proBNP R2 = 0.20, P< 0.0001; GFR R2 = 0.004,
P = 0.60; age R2 = 0.03, P = 0.015; BSA R2 = 0.008, P = 0.27).
Association between the individual
fibrotic measures and event-free survival
During follow-up, 47 (22%) patients reached the primary end-
point [all-cause death (n = 14), heart transplantation (n = 1),
life-threatening arrhythmia (n = 19), or HF hospitalization
(n = 14)]. Overall, 65 (31%) patients had at least one area of
focal fibrosis on CMR (Table 1), which were all distributed in
a non-ischaemic pattern. Twenty-seven (42%) of these patients
reached the primary endpoint as compared to 20 (14%) of the
patients without LGE (log-rank P< 0.0001; Figure 3A). When
we categorized the cohort into subgroups of above and below



















































































.. turnover markers – but not histological fibrosis – were associated
with worse prognosis when increased (log-rank PICP P = 0.03,
PIIINP P = 0.03, CVF P = 0.29; Figure 3B–D). No significant or
clinically relevant correlation between PICP or PIIINP and LVEF or
LVEDVi were found (online supplementary Figure S4).
Combining late gadolinium
enhancement and PICP provides
additional prognostic information
Late gadolinium enhancement and both blood fibrosis biomark-
ers (PIIINP and PICP) were associated with the primary com-
bined outcome, but only LGE and PICP remained associated after
adjustment for LVEF, eGFR, BMI, NT-proBNP, MRA use, diabetes,
sex and age (P = 0.001 and P< 0.001, respectively; Table 2). We
examined the shape of these associations using restricted cubic
spline of the (continuous) fibrosis markers adjusted for the clin-
ical parameters (online supplementary Figure S5). None of these
associations deviated from a linear relationship (P> 0.05). Finally,
we evaluated the predictive value of PICP and LGE individually
and combined when added to the clinical parameters, using a
series of nested models (Figure 4). The addition of the individual
fibrosis markers (i.e. PICP or LGE) did not significantly improve
the discrimination (ΔC-statistic: 0.033, P = 0.38 and ΔC-statistic:
0.059, P = 0.09, respectively; Figure 4A), neither did the combina-
tion of LGE and PICP (ΔC-statistic: 0.072, P = 0.07; Figure 4A).
LGE and PICP did improve the goodness-of-fit as individual mark-
ers (LHR chi-square for LGE: P< 0.001; LHR chi-square for PICP:
P< 0.003; Figure 4B). Combining both LGE and PICP improves the
goodness-of-fit even more compared to the individual markers
(P = 0.007). Reclassification of patients did not improve by adding
only LGE or PICP, but again, the combination of LGE and PICP
did (NRI: 0.28, P = 0.02; and IDI: 0.139, P = 0.01; Figure 4C,D).
The addition of PIIINP and CVF did not improve the C-statistics,
the goodness-of-fit or the reclassification. These results indicate
that both focal, non-ischaemic fibrosis by LGE-CMR and circu-
lating PICP are the most informative myocardial fibrosis determi-
nants related to long-term outcome, even after adjusting for clinical
parameters (Graphical Abstract).
In addition, patients were categorized into presence (LGE+)
or absence (LGE-) of LGE with subgroups of PICP levels above
(PICP+) or below (PICP-) the median, resulting in four groups at
baseline (online supplementary Table S1). Here, DCM patients with
LGE+/PICP+ had a significantly worse outcome as compared to
the other groups (log-rank P< 0.001; Figure 5). Interestingly, in the
subgroup of patients with LVEF >35%, the high fibrotic risk profile
LGE+/PICP+ had a significantly worse outcome as compared to
the other groups, showing a clear separation of patients with LGE+
with or without high levels of PICP (log-rank P< 0.001, online
supplementary Figure S6).
Alterations of fibrotic pathways in the
heart
In order to explore the cardiac pathophysiological changes asso-
ciated with fibrosis extent, genome-wide transcriptome analysis
© 2021 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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Table 1 Demographic, clinical and biochemical characteristics at baseline in all patients and in patients classified
according to non-invasive fibrosis assessment using cardiac magnetic resonance imaging and serum carboxy-terminal
propeptide of procollagen type I
Total (n = 209) LGE− (n = 144) LGE+ (n = 65) P-value
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Demographics
Age at diagnosis (years) 54±13 (18–80) 54± 13 54±12 NS
Male sex 136/209 (65%) 93/144 (65%) 43/65 (66%) NS
Heart rate (bpm) 75±17 72± 13 76±15 NS
Hypertension 84/209 (40%) 56/144 (39%) 28/65 (43%) NS
Diabetes mellitus 21/209 (10%) 16/144 (11%) 5/65 (8%) NS
Atrial fibrillation 52/209 (25%) 33/144 (23%) 16/65 (25%) NS
LBBB 52/209 (25%) 36/144 (25%) 16/65 (25%) NS
NSVT 59/209 (28%) 34/144 (24%) 25/65 (39%) 0.032
Duration of symptoms (months) 2 [0–5] 2 [0–4] 2 [0–7] NS
Presentation in outpatient clinic setting 165/209 (79%) 115/144 (80%) 50/65 (77%) NS
Genetic diagnostic yield
Core panel + TTN 136/209 (65%) 95/144 (66%) 41/65 (63%) NS
Pathogenic mutation 29/136 (14%) 18/95 (19%) 11/41 (27%) NS
TTN 16/29 (8%) 8/18 (44%) 8/11 (73%) NS
LMNA 3/29 (1%) 1/18 (6%) 2/11 (18%) NS
Presentation
Family history of DCM 35/209 (17%) 23/144 (16%) 12/65 (19%) NS
NYHA class III or IV 61/209 (29%) 34/144 (34%) 27/65 (42%) 0.013
Out of hospital cardiac arrest 13/209 (6%) 8/144 (6%) 5/65 (8%) NS
Lab
AST (U/L) 24 [19–33] 24 [18–32] 25 [20–36] NS
ALT (U/L) 26 [20–35] 26 [20–34] 29 [21–38] NS
Alkaline phosphatase (U/L) 82 [64–99] 83 [67–100] 79 [63–95] NS
eGFR (mL/min/1.73 m2) 72 [61–86] 75 [64–88] 68 [56–80] 0.008
NT-proBNP (ng/L) 557 [191–1636] 367 [128–1228] 1032 [360–3078] <0.001
CRP (mg/L) 3 [1–7] 3 [2–6] 3 [0–9] NS
hs-TnT (ng/L) 11 [7–25] 10 [6–18] 19 [10–42] 0.001
PICP (ng/mL) 78 [64–102] 77 [63–97] 85 [66–110] NS
PIIINP (ng/mL) 4 [3.2–6.4] 4 [3.1–5.6] 5 [3.5–7.4] 0.005
Medication
Beta-blocker 174/209 (83%) 122/144 (85%) 52/65 (80%) NS
ACE inhibitor/ARB 185/209 (89%) 124/144 (86%) 58/65 (89%) NS
Loop diuretic 112/209 (54%) 73/144 (51%) 39/65 (60%) NS
Aldosterone antagonist 74/209 (35%) 49/144 (34%) 25/65 (39%) NS
CMR
LVEDVi (mL/m2) 136± 53 135± 56 138± 47 NS
LVESVi (mL/m2) 92± 50 90± 53 97± 45 NS
LVEF (%) 34±12 35± 12 32±12 0.04
Stroke volume, indexed (mL/m2) 43±14 44± 14 41±14 NS
LV mass index (g/m2) 75± 27 74± 28 76± 23 NS
RVEDVi (mL/m2) 89± 32 88± 34 89± 26 NS
RVESVi (mL/m2) 48± 27 48± 29 49± 23 NS
RVEF (%) 47±14 47± 14 45±13 NS
LAVI (mL/m2) 54± 24 53± 24 56± 22 NS
Endomyocardial biopsy
Cardiac inflammation 71/209 (34%) 55/132 (42%) 16/64 (25%) 0.027
CD3 (cells/mm2) 6 [3–9] 6 [4–10] 5 [3–7] 0.003
CD45 (cells/mm2) 9 [4–12] 10 [6–14] 8 [5–11] 0.020
Collagen volume fraction (%) 7 [4–11] 6 [4–10] 9 [4–14] 0.009
ACE, angiotensin-converting enzyme; ALT, alanine aminotransferase; ARB, angiotensin receptor II blocker; AST, aspartate aminotransferase; CMR, cardiac magnetic resonance;
CRP, C-reactive protein; DCM, dilated cardiomyopathy; eGFR, estimated glomerular filtration rate; hs-TnT, high-sensitivity troponin T; LAVI, indexed left atrial volume; LBBB,
left bundle branch block; LGE, late gadolinium enhancement; LVEDVi, indexed left ventricular end-diastolic volume; LVEF, left ventricular ejection fraction; LVESVi, indexed left
ventricular end-systolic volume; NSVT, non-sustained ventricular tachycardia; NT-proBNP, N-terminal pro B-type natriuretic peptide; NYHA, New York Heart Association;
PICP, carboxy-terminal propeptide of procollagen type I; PIIINP, amino-terminal propeptide of procollagen type III; RVEDVi, indexed right ventricular end-diastolic volume;
RVEF, right ventricular ejection fraction; RVESVi, indexed right ventricular end-systolic volume.
© 2021 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
Multilevel assessment of myocardial fibrosis in DCM 939
Figure 2 Correlation between collagen volume fraction (CVF) in cardiac tissue and serum carboxy-terminal propeptide of procollagen type
I (PICP) in the total cohort and heart failure severity. PICP levels and histological CVF correlated in the total cohort (A) and even more so in
patients with severe heart failure in terms of left ventricular ejection fraction (LVEF) <35% (B), New York Heart Association (NYHA) class ≥III
(C), or both (D).
(RNA-sequencing of EMB) was performed in a representative, but
limited number of patients with available spare EMBs, categorized
at baseline according to the four subgroups (n = 34; online supple-
mentary Table S2). Principal component analysis (PCA) revealed
a distinct clustering of RNA transcript levels separating three
groups of patients: low degree of fibrosis (LGE-/PICP-), interme-
diate degree of fibrosis (LGE-/PICP+ and LGE+/PICP-), and high
degree of fibrosis (LGE+/PICP+) (Figure 6). Gene set enrichment
analysis with predefined KEGG and GO biological process terms
revealed significant alterations in inflammation, extracellular matrix
(ECM) and cardiac fibrosis pathways when comparing the high
degree to the low degree of fibrosis patients [e.g. ECM-receptor
interaction (hsa04512), focal adhesion (hsa04510) and NF-κB sig-
nalling (GO: 0038061); q< 0.001; online supplementary Table S3).
Further analysis with the IPA® software validated these findings
and identified NF-κB signalling and cardiac fibrosis among the top
pathways which are differentially expressed between patients with
LGE+/PICP+ vs. LGE-/PICP- (online supplementary Figure S7). The
main genes which were enriched in multiple of these pathways play
a role in inflammation, apoptosis and fibrosis (NFKB, TNC, PTX3,
































This is the first study in idiopathic DCM patients that integrated
EMB, CMR imaging, and collagen biomarkers to assess cardiac
fibrosis. It allowed us to evaluate each diagnostic modality inde-
pendently, but also its combined value for the risk stratification of
idiopathic DCM patients. The main novel findings can be summa-
rized as follows: (i) presence of LGE and elevated circulating PICP
levels are independent prognostic predictors; (ii) the combination
of circulating PICP and presence of LGE improves risk stratifica-
tion even more than either parameter alone, and (iii) the subgroup
characterized by LGE presence and elevated PICP has an evident
pro-fibrotic and pro-inflammatory transcriptome profile in cardiac
tissue compared to the other risk groups.
Prognostic value of fibrosis
In this multimodality imaging-biomarker-biopsy study, presence of
focal LGE and elevated PICP values were independent predictors
of outcome, whereas cardiac biopsy-derived fibrosis and elevated
PIIINP values were not. The presence of LGE in DCM patients is
© 2021 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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Figure 3 Long-term outcomes in dilated cardiomyopathy patients classified according to different fibrosis assessments. (A) Late gadolinium
enhancement (LGE), (B) carboxy-terminal propeptide of procollagen type I (PICP), and (C) amino-terminal propeptide of procollagen type III
(PIIINP) are associated with worse prognosis. Histological fibrosis (D) is not. CVF, collagen volume fraction.
Table 2 Univariate and multivariable models for combined endpoint
Fibrosis assessment Unadjusted analysis Adjusted analysisa
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
HR (95% CI) P-value HR (95% CI) P-value
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
LGE 3.7 (2.0–6.5) <0.001 3.54 (1.9–6.6) <0.001
PICP, ng/mL 1.02 (1.01–1.03) <0.001 1.02 (1.01–1.03) 0.001
PIIINP, μg/mL 1.07 (1.02–1.12) 0.004 1.06 (0.94–1.11) NS
CVF, % 1.07 (0.99–1.16) NS 1.05 (0.97–1.15) NS
CI, confidence interval; CVF, collagen volume fraction; HR, hazard ratio; LGE, late gadolinium enhancement; PICP, carboxy-terminal propeptide of procollagen type I; PIIINP,
amino-terminal propeptide of procollagen type III.
aAdjusted for left ventricular ejection fraction, estimated glomerular filtration rate, body mass index, N-terminal pro B-type natriuretic peptide, mineralocorticoid receptor
antagonist use, diabetes, sex and age.
known to be associated with adverse outcome including response
to therapy, HF, ventricular arrhythmias, sudden cardiac death and
all-cause mortality.1,5,6,24 This study showed for the first time that
circulating PICP adds further value to prognostication in DCM
patients, even beyond LGE and other well-known predictors of
outcome including sex, age, NYHA class, renal function, LVEF










. PICP might be of additional value to improve risk stratification in
patients with LGE+ and LVEF >35%, although these results should
be interpreted with caution due to the relatively small subgroup
population. Serum PICP has been reported as a marker of colla-
gen type I turnover in cardiac diseases which are associated with
myocardial fibrosis,25,26 and increased levels predict adverse out-
come in populations with ischaemic HF and HF with preserved
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Figure 4 Evaluation of the predictive value of carboxy-terminal
propeptide of procollagen type I (PICP) and late gadolinium
enhancement (LGE) after adjustment for clinical parameters using
a series of nested models. PICP and LGE did not significantly
improve discrimination based on Harrel’s C-index, neither did the
combination of LGE and PICP (A). The combination of PICP and
LGE improves the goodness-of-fit (B) and reclassification (C,D)
compared to the individual markers. IDI, integrated discrimination





















































































Figure 5 Long-term outcomes in dilated cardiomyopathy
patients classified according to presence (+) or absence (−) of
late gadolinium enhancement (LGE) and above (+) or below (−)
median values of carboxy-terminal propeptide of procollagen type
I (PICP). Dilated cardiomyopathy patients with LGE+/PICP+ had
a significantly worse outcome as compared to the other groups.
ejection fraction.8–10 Our finding is unique, as the combination of
two non-invasive techniques including LGE and PICP provides fur-
ther risk stratification for DCM patients without the need for inva-
sive EMB. The prognostic value of fibrosis in cardiac tissue provided
conflicting results in previous studies.12,13 These contraindications
and the fact that histological CVF is not associated with outcome in
our study population could be related to (i) histological CVF pre-
dominantly reflects reactive fibrosis considered to be reversible
and is not directly associated with cell death,27 and (ii) a substantial
part of DCM patients has myocardial fibrosis with a patchy distri-
bution that, in combination with the possibility of sampling error
and small tissue samples, can influence (and weaken) the prognostic
value of EMB-derived histological fibrosis.
Molecular signs of inflammation
and fibrosis
Our enrichment analysis reveals that genes in pro-inflammatory
and pro-fibrotic pathways are significantly higher expressed in car-
diac tissue of idiopathic DCM patients with elevated PICP and LGE
values (e.g. NFKB, TNC, PTX3, IL1B, IL4, COL1A1, COL1A2, COL3A1,
and CTGF). This would suggest the validity of fibrosis detection by
LGE and PICP, as the subsequent generated subgroups are asso-
ciated with distinct cardiac transcriptomic profiles. Indeed, cardiac
inflammation and fibrosis are key pathophysiological mechanisms in
the failing heart which are closely linked to each other.28 Most of
the differentially expressed genes are involved in the signalling path-
ways of NF-κB (nuclear factor kappa-light-chain-enhancer of acti-
vated B cells) and fibrosis. NF-κB transcription factors are involved
in many physiological processes, including innate and adaptive
immune responses, inflammation, cell death, and tissue remod-
elling. Crosstalk of NF-κB with other pro-fibrotic cell-signalling
© 2021 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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Figure 6 Principal component analysis based on cardiac
RNA-sequencing data of dilated cardiomyopathy patients classi-
fied according to presence (+) or absence (−) of late gadolinium
enhancement (LGE) and above (+) or below (−) median val-
ues of carboxy-terminal propeptide of procollagen type I (PICP).
Principal component analysis revealed a distinct clustering of
RNA transcript levels separating three groups of patients: low
degree of fibrosis (LGE-/PICP-), intermediate degree of fibro-
sis (LGE-/PICP+ and LGE+/PICP-), and high degree of fibrosis
(LGE+/PICP+).
networks might be related to ongoing inflammation and cardiac
remodelling.29,30
Clinical implications and future
directions
Myocardial fibrosis in idiopathic DCM patients can present itself
in various forms and states, which are difficult to distinguish. The
combination of LGE and PICP could capture the most complete
fibrotic burden, given the prognostic relevance and the accompa-
nied pro-fibrotic molecular state. This high fibrotic burden could
identify patients at higher risk for adverse outcome, even beyond
well-known clinical risk factors. One smaller study using EMB and
circulating PICP in 25 DCM patients demonstrated that both lev-
els of PICP and histological fibrosis decreased after treatment with
spironolactone.31 In the HOMAGE (‘Heart Omics in AGEing’) trial,
527 persons who are at risk of developing HF demonstrated similar
decreasing levels of PICP after spironolactone treatment, with cor-
responding reductions in ventricular pre- and afterload.32 Also, a
prospective study of 60 CRT patients showed that lower circulating
PICP levels are associated with a positive response to CRT, defined
by a combination of event-free survival, no HF hospitalization and
occurrence of left ventricular reverse remodelling.33 The DANISH
trial questioned the use of ICD in DCM patients.34 Identification



















































































.. for this dilemma, as increased levels of collagen type I was associ-
ated with appropriate ICD-delivered therapy in 70 DCM patients.35
These findings highlight the potential clinical value of circulating
PICP in combination with CMR as markers to monitor disease pro-
gression, and to identify patients who benefit from spironolactone
treatment and ICD or CRT implantation.36 However, temporal
changes in biomarkers of collagen metabolism and/or imaging are
required to further validate these findings. Also, collagen pep-
tides (e.g. PICP) reflect systemic collagen metabolism which is
affected by concomitant non-cardiac diseases as well and should
therefore always be interpreted in conjunction with structural and
functional cardiac parameters from non-invasive imaging.7 Future
studies in DCM patients should focus on the pivotal question as
to whether we could follow and predict disease progression using
non-invasive PICP levels in combination with CMR, and what type
of targeted therapy could be employed to prevent or delay adverse
outcome.
Limitations
The majority of CMRs in this study had no T1 or extracellular
volume mapping available, since this CMR sequencing was not
available before 2016 in our centre. As patient recruitment was
performed over an extended period of time, sample quality may
have been effected over time. However, all samples were handled
using the same standardized operating procedures and stored at
−80∘C without any freeze–thaw cycles. Although we included
well-known clinical prognostic predictors in our clinical model,
we could not extend the number of variables in this model due
to the limited number of events and subsequent statistical power.
Unfortunately, no established cut-off value for PICP exists, as it
may also depend on the aetiology of the pathology and the degree
of active fibrosis. Evaluating optimal prognostic cut-off values of
fibrosis parameters was beyond the scope of this study and further
research is needed to do so.
We did perform genetic screening in all patients who consented
(65%); however, the number of pathogenic gene variants did not
provide sufficient power to allow risk stratification based on
specific gene variants, although variants seemed equally distributed
among groups. Also, external validation in another representative
DCM cohort would be desirable to validate our findings.
Conclusions
Using a multiparametric approach to detect fibrosis indicates that
the combination of LGE and PICP provides additive prognostic
value in idiopathic DCM patients. Patients with LGE and elevated
PICP have a myocardial pro-fibrotic and pro-inflammatory tran-
scriptomic profile.
Supplementary Information
Additional supporting information may be found online in the
Supporting Information section at the end of the article.
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